An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Recruiting in Palo Alto (17 mi)
+259 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Pfizer
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
Eligibility Criteria
Inclusion Criteria
histologically or cytologically proven diagnosis of non-small cell lung cancer
positive for the ALK fusion gene (test provided by a central laboratory)
must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
See 1 more
Treatment Details
Interventions
- Docetaxel (Taxane)
- Pemetrexed (Antifolate)
- PF-02341066 (Tyrosine Kinase Inhibitor)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: PF-02341066Experimental Treatment1 Intervention
Group II: Pemetrexed or DocetaxelActive Control2 Interventions
Investigator selection of either pemetrexed or docetaxel as the active comparator
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Colorado Denver (CTRC)Aurora, CO
The Ottawa Hospital Cancer CentreOttawa, Canada
Stanford University-Cancer CenterPalo Alto, CA
Tennessee Oncology, PLLCMurfreesboro, TN
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
PfizerLead Sponsor